DSP 9599

Drug Profile

DSP 9599

Alternative Names: DSP9599

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 14 Jun 2013 Pharmacokinetics, adverse events & pharmacodynamics data from a phase I trial in Healthy volunteers presented at the 23rd European Meeting on Hypertension (ESH-2013)
  • 31 Jan 2013 Discontinued - Phase-I for Hypertension in Japan (PO)
  • 31 Mar 2012 Phase-I clinical trials in Hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top